期刊
VACCINES
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/vaccines10122062
关键词
DNA vaccine; rainbow trout; VHS; IHN; field trial
资金
- Italian Ministry of Health
- Independent Research Fund Denmark [IZSVe RC 09/18]
- [9041-00227B]
Despite the negative impact of VHS and IHN on European rainbow trout farming, no vaccines are commercially available in Europe. This study developed and tested two DNA vaccines encoding the glycoproteins of recent Italian VHSV and IHNV isolates. The results showed that the DNA vaccines were safe and efficient in reducing the impact of VHS and IHN in farmed rainbow trout.
Despite the negative impact of viral hemorrhagic septicemia (VHS) and infectious hematopoietic necrosis (IHN) on European rainbow trout farming, no vaccines are commercially available in Europe. DNA vaccines are protective under experimental conditions, but testing under intensive farming conditions remains uninvestigated. Two DNA vaccines encoding the glycoproteins (G) of recent Italian VHSV and IHNV isolates were developed and tested for potency and safety under experimental conditions. Subsequently, a field vaccination trial was initiated at a disease-free hatchery. The fish were injected intramuscularly with either the VHS DNA vaccine or with a mix of VHS and IHN DNA vaccines at a dose of 1 mu g/vaccine/fish, or with PBS. At 60 days post-vaccination, fish were moved to a VHSV and IHNV infected facility. Mortality started 7 days later, initially due to VHS. After 3 months, IHN became the dominant cause of disease. Accordingly, both DNA vaccinated groups displayed lower losses compared to the PBS group during the first three months, while the VHS/IHN vaccinated group subsequently had the lowest mortality. A later outbreak of ERM caused equal disease in all groups. The trial confirmed the DNA vaccines to be safe and efficient in reducing the impact of VHS and IHN in farmed rainbow trout.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据